Acadia Pharmaceuticals (ACAD) Accumulated Expenses (2010 - 2026)

Acadia Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $31.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 88.95% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at $31.4 million (down 88.95% YoY), while the FY2025 annual figure was $266.2 million, up 628.33% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $31.4 million, down from $266.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $334.8 million in Q3 2025, with the low at $21.2 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $105.8 million (2022), against an average of $134.4 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses soared 1368.79% in 2024, then plunged 90.95% in 2025.
• Acadia Pharmaceuticals' Accumulated Expenses stood at $28.0 million in 2022, then soared by 52.44% to $42.7 million in 2023, then retreated by 14.44% to $36.6 million in 2024, then surged by 628.33% to $266.2 million in 2025, then plunged by 88.19% to $31.4 million in 2026.
• Business Quant data shows ACAD's Accumulated Expenses at $31.4 million in Q1 2026, $266.2 million in Q4 2025, and $334.8 million in Q3 2025.